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ABSTRACT
Introduction Cancer-related fatigue (CRF) is one of the
most common and debilitating adverse effects of cancer
and its treatment reported by cancer survivors. Physical
activity, psychological interventions and management of
concurrent symptoms have been shown to be effective
in alleviating CRF. This pilot randomised controlled trial
(RCT) will determine the feasibility of a telehealth CRF
clinic intervention (T-CRF) to implement evidence-based
strategies and assess the impact of the intervention on
CRF and other clinical factors in comparison to usual
care.
Methods and analysis A parallel-arm (intervention vs
usual care) pilot RCT will be conducted at the Princess
Alexandra Hospital in Queensland, Australia. Sixty cancer
survivors aged 18 years and over, who report moderate
or severe fatigue on the Brief Fatigue Inventory and meet
other study criteria will be recruited. Participants will
be randomised (1:1) to receive the T-CRF intervention
or usual care (ie, specialist-led care, with a fatigue
information booklet). The intervention is a 24-week
programme of three telehealth nurse-led consultations
and a personalised CRF management plan. The primary
objective of this pilot RCT is to determine intervention
feasibility, with a secondary objective to determine
preliminary clinical efficacy. Feasibility outcomes include
the identification of recruitment methods; recruitment
rate and uptake; attrition; adherence; fidelity; apathy; and
intervention functionality, acceptability and satisfaction.
Clinical and resource use outcomes include cancer
survivor fatigue, symptom burden, level of physical activity,
productivity loss, hospital resource utilisation and carer’s
fatigue and productivity loss. Descriptive statistics will be
used to report on feasibility and process-related elements
additional to clinical and resource outcomes.
Ethics and dissemination This trial is prospectively
registered (ACTRN12620001334998). The study protocol
has been approved by the Metro South Health and Hospital
Services Human Research Ethics Committee (MSHHS
HREC/2020/QMS/63495). Findings will be disseminated
through peer-reviewed publications, national and
international conferences and seminars or workshops.

STRENGTHS AND LIMITATIONS OF THIS STUDY
⇒ This randomised controlled trial (RCT) assesses a

⇒
⇒

⇒
⇒

‘telehealth cancer-related fatigue clinic’ intervention
embedded in the community setting as distinct from
the clinical setting.
This feasibility pilot RCT study will provide data for
an adequately powered effectiveness trial.
This study design will enable individualised treatment flexibility and compare interventions in a
real-world community setting to realistically inform
clinical and community practice directly.
This study is not powered to examine intervention
efficacy and does not assess regionality.
Due to the nature of the intervention, blinding of
the participants and treatment providers (cancer
nurses and intervention physiotherapist) will not be
possible.

Trial registration number Australian New Zealand
Clinical Trials Registry ID: ACTRN12620001334998;
Pre-results. Trial Version: Version 1.1. Last updated 10
December 2020.

INTRODUCTION
Background
Cancer-related fatigue (CRF) is one of the
most common and debilitating adverse
effects experienced by cancer survivors
during and after cancer treatment,1 2 with two
in three cancer survivors reporting some level
of fatigue, and one in three cases assessed as
severe.2 CRF differs to ‘normal’ fatigue as it
cannot not be relieved through rest and sleep,
and is defined as ‘a distressing persistent,
subjective sense of physical, emotional and/
or cognitive tiredness or exhaustion related
to cancer or cancer treatment that is not
proportional to recent activity and interferes
with usual functioning’.1 While the exact
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successful method to facilitate the systematic assessment
and management of CRF in cancer survivors.24 25 These
clinics are often physician-led, provided in well-resourced
centres, and require cancer survivors to attend face-to-
face appointments at the cancer centre.24 25 With CRF
being one of the most common unmet needs reported by
cancer survivors, it is key to develop and test more accessible and sustainable methods for delivering such CRF
clinics. First, with the increasing use of telehealth, especially in the post-COVID era, it is extremely important
to determine if a CRF clinic can be sufficiently delivered
using telehealth.26 27 Second, trained cancer nurses28 are
already managing a myriad of cancer symptoms and delivering psychological and physical activity interventions
in their practice,29 which are key evidence-based strategies for managing CRF. Nurses in partnership with allied
health practitioners, key members of multidisciplinary
cancer care, are the ideal workforce to lead CRF clinics
and enhance service accessibility, ultimately facilitating
implementation of evidence-based care and improving
CRF outcomes in cancer survivors.
Our pilot randomised controlled trial (RCT) seeks
to determine the feasibility of a community-based and
cancer nurse-led, telehealth CRF (T-CRF) intervention
and assess the preliminary efficacy of the intervention
on CRF and other clinical factors in comparison to usual
care for cancer survivors and carers. Specifically, this trial
will evaluate the feasibility of implementing the T-CRF
intervention within the community setting into routine
care by assessing recruitment, attrition, functionality,
acceptability, satisfaction with care, adherence among
participants and intervention fidelity among programme
administrators. This trial will also evaluate the preliminary efficacy of the T-
CRF intervention according to
clinical and resource outcomes including cancer survivor
fatigue, symptom burden, physical activity, productivity
loss, hospital resource utilisation and carer fatigue and
productivity loss. Preliminary efficacy data will be used
to determine appropriate effect sizes and other statistical
data that can be used in future statistical models to estimate sample sizes required to run the definitive clinical
effectiveness trials.
METHODS AND ANALYSIS
Study design
A parallel-group, pilot RCT (1:1, intervention vs usual
care) study design will be used to determine the feasibility and evaluate the preliminary efficacy of the T-CRF
intervention. More specifically, this pilot RCT will provide
feasibility and process data to inform the design of a fully
powered RCT that will compare the effects of a novel
clinic model of care verses usual care on the severity of
CRF and related symptom outcomes. The pilot study
design will incorporate individualised treatment flexibility in a real-world setting to provide realistic estimates
of effects when implemented in the definitive RCT.30 The
study protocol (v1.1) has been prepared in accordance
Ladwa R, et al. BMJ Open 2022;12:e059952. doi:10.1136/bmjopen-2021-059952
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mechanisms of CRF are unknown, its influence on the
quality of life and functional capacity of cancer survivors is
well established. CRF has long lasting negative impacts on
the physical, mental, emotional and social well-being of
people with cancer,3–9 often resulting in general weakness,
diminished concentration or attention, emotional instability and decreased motivation or interest to engage in
usual activities.1 10 CRF can also adversely affect the ability
to return to work and engage in meaningful social relationships and leisure activities; negatively affecting cancer
survivors’ mental health and quality of life.11 12 Moreover,
CRF can influence a cancer survivor’s willingness to
commence or continue with their cancer treatment, or
their willingness and ability to attend follow-up appointments, potentially influencing treatment outcomes and
survival.10 While the prevalence of CRF is high during
active treatment, many cancer survivors also continue to
report moderate to severe fatigue at 12 months post diagnosis and for several years after treatment completion.13
Additionally, caregivers of cancer survivors can also face
significant emotional, physical, psychosocial and spiritual
fatigue burden that affects their productivity, particularly while those they are caring for receive active treatment.11 14–17
Many studies have assessed pharmacological and non-
pharmacological strategies to reduce CRF.13 Despite their
prior use, pharmacological treatments (eg, modafinil,
erythropoietin, methylphenidate) are largely ineffective
for CRF, and may be potentially harmful to its users.18–20
Several guidelines, including the ‘National Comprehensive Cancer Network (NCCN) Clinical Practice
Guidelines in Oncology for CRF’, now recommend non-
pharmacological treatments including physical activity
(ie, aerobic exercise, resistance exercise, yoga), psychological interventions (ie, cognitive–behavioural therapy,
psychoeducational therapy), physical therapies (ie,
massage, acupuncture) and energy conservation techniques.1 10 A meta-analysis including 113 randomised clinical trials that involved 11 525 cancer survivors identified
that exercise (weighted effect size (WES): 0.30; 95% CI
0.25 to 0.36; p<0.001), psychological (WES: 0.27; 95% CI
0.21 to 0.33; p<0.001) or combined (WES: 0.26; 95% CI
0.13 to 0.38; p<0.001) interventions as the most effective
strategies for reducing CRF during and after cancer treatment when compared with pharmacologic interventions
and other therapies.21 In addition, there is also recent
evidence suggesting that the management of concurrent
symptoms also improves CRF.22
Despite high-quality evidence of effective management
strategies for CRF, it remains an unmet need for most
cancer survivors, suggesting that current management
strategies are not well implemented in clinical practice.1 2
A recent scoping review on the implementation of CRF
management strategies into clinical practice identified
a lack of high-
quality studies in the literature which
also highlights the disconnect between effective CRF
interventions and routine clinical care.23 As a key implementation strategy, the concept of a ‘CRF clinic’ is one
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Cancer Survivor
(Inclusion Criteria)

Cancer Survivor
(Exclusion Criteria)

Carer
(Inclusion Criteria)

Withdrawal Criteria
(If Applicable)

≥18 years of age
Have a definitive diagnosis of
solid tumour or haematological
cancer
Receive care at the Princess
Alexandra Hospital outpatient
clinics

Presence of severe mental,
cognitive or physical conditions
that would limit the person’s
ability to participate. This
ensures patients have the
capacity to provide informed
consent, and participation in
the study will not pose unethical
burden on the person.

≥18 years of age
Self-endorsing or identified by
cancer survivors as ‘a relative,
friend, or partner who you have
a close relationship with and
who assists you with medical
care on a regular basis and who
may or may not live in the same
residence as you and who is
not paid for their help’.

Altered mental capacity
resulting in inability
to provide continuing
informed consent.

Be 6-week post completion
of primary cancer treatment
(ie, surgery, radiotherapy,
chemotherapy) or have
completed at least 3 months
of maintenance treatment
(ie, hormone therapy,
immunotherapy chemotherapy)

Known prognosis of <6
months at the discretion of the
treating clinician. This ensures
participation in this study will
not pose unethical burden on
cancer survivors nearing end
of life.

The caregiver’s care recipient
must be participating in the
study.

Unforeseeable
circumstances where
participation in this study
may pose unethical burden
on the cancer survivor and/
or carer or hinder their
ability to provide informed
consent.

≥4 on the global fatigue score
of the Brief Fatigue Inventory

Medical conditions or
circumstances (eg, active
Eastern Cooperative Oncology infections) where participation
in this study may pose unethical
Group performance status of
burden on the cancer survivor
≤2
or hinder their ability to provide
informed consent or participate.
 
Not currently receiving
specialist palliative care
Have access to a telephone/
mobile device or a computer
and internet connection.
Agrees and has the capacity to
upload wearable device data

with the Standard Protocol Items: Recommendations for
Interventional Trials statement.31
Study setting
Cancer survivors and their carers will be recruited through
outpatient clinics of the Division of Cancer Services at the
Princess Alexandra Hospital (PAH), a tertiary hospital
located in Brisbane, Queensland, Australia.
Participants
Eligibility criteria
Cancer survivors experiencing moderate to severe fatigue
(ie, Brief Fatigue Inventory (BFI) score of 4 or greater32),
and who are receiving cancer treatment at the PAH will
be approached for recruitment. Eligible participants
will be over 18 years of age and be at least 6 weeks post
completion of primary cancer treatment (ie, surgery,
radiotherapy, chemotherapy) or have completed at
least 3 months of maintenance treatment (ie, hormone
therapy, immunotherapy, chemotherapy). One informal
carer of recruited cancer survivors will also be invited to
participate if they are over 18 years of age. Further details
Ladwa R, et al. BMJ Open 2022;12:e059952. doi:10.1136/bmjopen-2021-059952

Death

 

of eligibility criteria for carers and cancer survivors are
provided in table 1.
Recruitment and consent
Potentially eligible cancer survivors will be identified and
approached by their treating clinicians who will gauge
their interest in the study, provide a study brochure and
gain verbal consent to being approached by the research
team. Cancer survivors will be contacted by a research
team member, screened for eligibility and provided with
study information. After a time of reflection (at least 24
hours), cancer survivors will be invited to sign a consent
form (online supplemental material 1) to indicate their
willingness to participate. At the time of consent, cancer
survivor participants will be asked for their consent to
contact their primary informal carer. Informal carers
(individuals self-endorsed or identified by cancer survivors as a relative, friend or partner they have a close
relationship with and who assists them with care) will
be contacted by the research team, provided with study
information and after a time of reflection (at least 24
3
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Table 1 Study eligibility criteria
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Trial procedures
Sample size
Sixty cancer survivors experiencing moderate or severe
fatigue (n=30 per arm) will be recruited. This study is not
hypothesis testing; thus, power level is not the consideration underpinning sample size. Our chosen sample size
for this study falls within the range of recommendations
for preliminary studies of this nature.33 34 PAH service
data indicate a throughput of more than 30 cancer survivors per week. Of these, approximately 30%–50% will
report moderate-to-severe CRF.2 As our research team
is embedded within the clinical care team at the PAH,
we anticipate a high referral rate (~10 per week) and a
recruitment rate of ~5 per week following full eligibility
screening. All consented cancer survivors will be invited
to refer their informal carer to participate in the trial. The
sample size for informal carers is expected to be approximately 30, as we anticipate 50% of the carers referred by
recruited cancer survivors will agree to participate in the
study.
Randomisation and allocation
Randomisation occurs at the level of the cancer survivor
participant. Carer participants are assigned to the same
group as their cancer survivor. Computer-
generated
random numbers will be used to allocate cancer survivor
participants in a 1:1 ratio by a researcher not involved
in recruitment, intervention implementation or data
collection. Allocation numbers will be sealed in opaque
envelopes prepared by an independent researcher.
Randomisation will be blocked using random permuted
blocks of four and six to ensure that the groups are
balanced periodically within stratification groups. To
ensure equal distribution of participants with different
levels of fatigue, participants will be stratified by their
fatigue severity (moderate: 4–6 or severe 7–10 on the BFI
scale) at baseline.

Blinding
Outcome assessors and data analysts will be blinded to
group allocation. Participants will be advised not to reveal
their group allocation to the outcome assessor. Due to the
nature of intervention, trial participants and intervention
administrators will not be blinded to group allocation.
Intervention
All participants will be provided with a written 3-page
booklet on ‘Fatigue and Cancer’ published by Cancer
Council Australia,35 regardless of arm assignment.
Arm 1: the T-CRF clinic (intervention)
The overarching aim of the intervention is to systematbased strategies including,
ically implement evidence-
but not limited to the promotion of physical activities/
exercise intervention; delivery of psychological interventions; management of concurrent symptoms; and general
coping. The design of the T-CRF clinic is informed by
the NCCN CRF guidelines1 and incorporates CRF assessment, the development of management strategies, and
the provision of referral pathways. Specific components
of the T-
CRF clinic intervention are listed in online
supplemental material 3.
Briefly, after cancer survivor participant enrolment,
nurses working at the non-
government organisation
Cancer Council Queensland (CCQ) will receive a referral
from the research team indicating cancer survivor
medical and treatment histories; fatigue severity; physical activity behaviours; nutritional status; any contraindications to unsupervised exercise recommendations;
and a recommended clinic schedule at weeks 0–2, week
12–14 and week 24–26 post baseline (see figure 1). The
CCQ nurse will contact cancer survivor participants
directly to arrange three telehealth clinic appointments
and four booster phone calls, two between each clinic
appointment. During clinic consultations, nurses will:
(1) conduct a CRF assessment; (2) provide verbal education on fatigue management addressing: physical activity,
current symptoms and/or general coping; (3) codevelop
a CRF management plan including up to three Specific,

Figure 1 The telehealth cancer-related fatigue clinic model for cancer survivors follow-up. Schematic of the trial design. T1:
baseline; T2: 12–14 weeks post baseline; T2: 24–26 weeks post baseline; T4: 48 weeks post baseline. T-CRF, telehealth cancer-
related fatigue.
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hours), they will be invited to sign a consent form (online
supplemental material 2) to indicate willingness to participate in the trial.

Open access

Measurable, Achievable, Relevant, and Time bound
(SMART) goals that address physical activity, current
symptoms and/or general coping; and (4) facilitate referrals. During consultations, CCQ nurses will be guided by
a nurse clinic checklist that details the required components of each clinic session. Where referral pathways at
PAH are not available or appropriate, CCQ nurses will
refer cancer survivors to community organisations or to
their primary care provider to coordinate community
referrals. Cancer survivor participants will be emailed or
posted a copy of their CRF management plan developed
by the research team (see online supplemental material
4).
CCQ nurses will make general recommendations for
exercise intensity levels and supervision based on an
adapted clinical pathway triage algorithm developed by
Stout et al36 (figure 2). This decision-making support tool
enables personalised condition assessment, risk stratification and referral to optimal settings for exercise promotion in cancer survivors—in this regard, to address CRF.
Participants who require exercise supervision will be
referred to the cancer physiotherapist of the PAH, who
will offer face-to-face or telehealth group exercise sessions
over 12 weeks (once weekly) or 6 weeks (twice weekly)
Ladwa R, et al. BMJ Open 2022;12:e059952. doi:10.1136/bmjopen-2021-059952

or one-on-one exercise sessions including aerobic, resistance, flexibility and balance activities depending on individual need and available equipment. Face-to-face group
exercise allows for eight participants supervised by two
physiotherapists, and telehealth group exercise allows
for five participants supervised by one physiotherapist.
Attendance at supervised exercise sessions or referrals to
community exercise programmes will be recorded as a
measure of adherence to the intervention. Between the
first and second T-CRF clinics, CCQ nurses will provide
two 10–20 min follow-up booster phone calls to participants to monitor progress towards meeting SMART goals
and offer support. Adherence to the intervention will be
monitored using clinic and phone review checklists.
Intervention training and adverse events (AEs)
CCQ nurses have extensive experience in caring for
cancer survivors. Intervention physiotherapists are nationally accredited by the Australian Physiotherapy Association and have extensive experience caring for cancer
survivors. CCQ nurses will receive additional training
with regards to all components of the T-CRF intervention.
Briefly, training will comprise a written manual with information on how to deliver the intervention, and material
5
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Figure 2 Algorithm for determining exercise intensity and levels of supervision. The pathway is intended to stratify individuals
to higher (red), intermediate (yellow) or lower (green) condition complexity, which provides insight into the level of supervision
and guidance that individuals may need to successfully engage in exercise and informs referrals. OPD, outpatient department;
PAH, Princess Alexandra Hospital; YMCA, Young Men's Christian Association.
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Intervention fidelity
In addition to the use of clinic and phone booster checklists, participants and CCQ nurses will be asked to consent
to the audio recording of all nurse-led clinics for quality
assurance and to recheck any data or information. Fidelity
of the intervention will be assessed using the framework
for behavioural interventions recommended by the
National Institutes of Health37 38 as outlined in table 2. It
is expected that some of these strategies will be refined
through the conduct of the pilot trial.
Arm 2: control (usual care)
The control arm consists of usual follow-up care plus a
written 3-page booklet on Fatigue and Cancer published
by Cancer Council Australia.35 Follow-up arrangements at
the PAH will vary primarily according to cancer type, and
is determined by the treating surgeon, medical oncologist
or radiation oncologist through a specialist-led model.
Baseline and follow-up procedures
Study schedules for data collection and a schematic of the
trial design are shown in table 3 and figure 1, respectively.
Clinical characteristics and demographics (ie, age, gender,
ethnicity, highest level of education, living arrangements,
marital status, employment) will be collected directly
from participants and medical records by outcome assessors at baseline (T1). All participant-reported outcomes
will be collected at baseline (T1), 12–14 weeks (T2),
24–26 weeks (T3) and 48 weeks (T4) post baseline.
Instruments will be self-administered via online surveys
using Research Electronic Data Capture (REDCap) or
interviewer-
administered by blinded outcome assessors
via telephone. Participants and healthcare providers will
be invited to opt into a semistructured interview at T4
either face to face, by telephone or through videoconferencing as per interviewee preference. Semistructured
6

interviews will be used to collect data on intervention
functionality, acceptability and satisfaction that will be
guided by the Consolidated Framework for Implementation Research (CFIR) (see online supplemental material
5 for the interview guide).
Outcomes
Primary outcomes include measurements relevant to
the feasibility of conducting large-scale RCT. Secondary
outcomes involve measurements of preliminary clinical
efficacy intended for use in the full-scale trial.
Trial feasibility
Feasibility of the T-CRF trial is the primary outcome of
this pilot RCT and will be assessed using the following
process outcomes: recruitment and uptake, attrition,
adherence, fidelity, apathy, functionality, acceptability
and satisfaction with the intervention (see table 4).
Recruitment, intervention uptake and attrition will
be assessed using screening logs and online REDCap
survey data. Intervention adherence and fidelity of intervention nurses will be evaluated through assessing the
number of items completed on the nurse-clinic checklist
during consultations and booster phone calls. Apathy
will be measured using the Self-Reported Apathy Evaluation Scale.39 Intervention functionality, acceptability
and satisfaction will be evaluated using a cancer survivor
satisfaction survey as well as stakeholder semistructured
interviews. Semistructured interviews will be conducted
with intervention nurses and other healthcare providers
involved in providing care for cancer survivor participants. Cancer survivors and carers allocated to the T-CRF
trial arm will be invited to participate in an interview at
the 12-month time point. Guiding questions (see online
supplemental file 5) and analysis of the interviews will be
guided by the CFIR.
Clinical outcomes
A secondary goal is to assess the preliminary efficacy of
the T-
CRF intervention on cancer survivor’s fatigue,
symptom burden, productivity loss, hospital resource
utilisation, level of physical activity, as well as carer’s
fatigue, and carer’s productivity loss. These outcomes
will be assessed using validated self-report measures and
medical record data as described in table 3. Additionally,
participants will be required to wear a Garmin wrist-worn
activity monitoring device at no additional cost. This will
measure physical activity (pedometer: number of steps
per day, altimeter: number of stairs climbed, total hours
doing moderate intensity exercise based on heart rate per
day and total hours slept per day).
Withdrawal and study termination
Any participant can withdraw from the study at any time
and for any reason without prejudice. If a cancer survivor
or carer participant is withdrawn because of an AE, the
up care
investigator will arrange for appropriate follow-
until the AE is resolved or has stabilised. Unresolved AEs
will be followed until the last scheduled follow-up visit or
Ladwa R, et al. BMJ Open 2022;12:e059952. doi:10.1136/bmjopen-2021-059952
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on communication, motivational interviewing and cognitive behavioural techniques; and a 1-day workshop incorporating a mix of written mock intervention case studies
and motivational interviewing role play activities.
Participants requiring supervised exercise require
medical clearance from their treating oncology team and
will undergo a comprehensive initial assessment with vital
signs monitored pre and post exercise by the intervention
physiotherapist to ensure safety. Procedural guidelines
are in place to deal with unexpected exercise-related AEs
as clinically indicated. Existing incident reporting structures at the PAH will be followed and the participant’s
treating clinician, cancer nurse coordinator and CCQ
intervention nurses will be informed. A detailed review of
cancer survivor participant assessment forms and exercise
history will be undertaken by an independent oncologist.
For participants who experience any emotional distress
during CCQ intervention nurse consults will be referred
to the CCQ counselling service consisting of nurse counsellors and psychologists for evaluation and clinical
management.

Open access

Study design

Study design procedures have been designed to ensure tha the study can adequately test its hypotheses
in relation to underlying theory and clinical practices.

Training providers

Standardised provider training includes procedures to ensure that interventionists have been
satisfactorily trained to deliver the intervention to cancer survivor participants. This training will involve:
► Provision of a study manual to all staff which includes:
Generic study-related information: study overview, reporting/documentation guidelines,
communication flowchart, rationale for the study treatment, self-management goal setting,
motivational interviewing and health coaching.
Intervener-specific information: job description, intervention protocol, quality assurance and
monitoring
► The trained registered nurse responsible for the intervention will have approximately 4 hours of pre-
reading modules developed by the chief investigators, and approximately 4 hours of practical training.
This will include:
Clinical management of CRF
NCCN CRF guidelines
Exercise and physical activity advice
Provision of self-management support (including collaborative goal setting and motivational
interviewing, sleep hygiene and energy conservation)
Education about referral pathways for services within Princess Alexandra Hospital referral flow charts
and contact details for community services
► The data collector will have necessary prereading and training. This will include:

Data collection tools and procedures to be used
NCCN CRF guidelines for the screening and assessment of CRF

Delivery of treatment Intervention procedures will be monitored to improve delivery of intervention and comparison of
conditions, and ensure that the intervention is delivered as intended, through:
► The nurse-led clinics will be audio and/ or video recorded and checked for quality assurance.
► The intervention fidelity will be closely monitored and discussed during the monthly meeting for the
first 3 months of the trial between the intervention nurses, intervention physiotherapist, research
assistants and/or chief investigators.
► Omissions and/or protocol deviations will be reviewed on an individual basis.
► Intervention checklist completed at the end of each intervention to allow protocol deviation tracking
across interveners and conditions.
► Minimising contamination between conditions by training interventionists to address cancer
survivor participant questions about randomisation and their assigned condition using non-biased
explanations.
Receipt of treatment Treatment receipt focuses on the cancer survivor participant and includes procedures to assure that the
treatment was both received and understood. This goal will be achieved by:
► Ensuring participants understand the information provided for each intervention, by checking through
use of active questions and behavioural observations
Enactment of
Enactment of treatment skills includes processes to monitor and improve cancer survivor participant
treatment skills
ability to perform treatment-related behavioural skills and cognitive strategies in relevant real-life settings
as intended. This goal will be achieved by:
► ensuring participants are aware of the follow-up schedules and responsibilities of all health
professionals.
► ensuring participants will have a copy of the completed self-management care plan including all care
responsibilities and goals set for the individual
CRF, cancer-related fatigue ; NCCN, National Comprehensive Cancer Network.

until no longer indicated, per investigator discretion. In
addition to AEs, other reasons for removal of participants
from the study might include, but are not limited to, withdrawal of consent, administrative decision by the principal
investigator or responsible organisation, or protocol deviation. If a participant asks or decides to withdraw, all efforts
will be made to complete and report the observations,
especially primary and secondary objectives, as thoroughly
Ladwa R, et al. BMJ Open 2022;12:e059952. doi:10.1136/bmjopen-2021-059952

as possible up to the date of withdrawal. The primary
reason for withdrawal (where known) will be identified
and recorded on a case report form, along with the date of
withdrawal. Withdrawal criteria are listed in table 1.
STATISTICAL ANALYSIS
Descriptive statistics will be used to report on feasibility
and process-
related outcomes (eg, recruitment rate,
7
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Table 2 Intervention fidelity strategies

Open access

Baseline
Process

EST time
(min)

Consent

(T1)

Week 2*

Self-report Data Collection — Cancer Survivor Participant
Garmin Education
5
X
 
X

 

Week 13±1*

Week 25±1*

(T2)

(T3)

Week 49±1
(T4)

 

 
 

 
 

 
 

 

 

 

 

PG-SGA SF (10
items)

5

BFI (10 items)

3

 

X

 

X

X

X

MSAS (32 items)

5

 

X

 

X

X

X

AAS and Fruit and
Vegetable intake (8
items)

5

 

X

 

X

X

X

AES-S (18 items)

5

 

X

 

X

X

X

Productivity (3 items)

2

 

X

 

X

X

Interview

15

 

 

 

X
 

Medical Record Data Collection — Cancer Survivor Participant

 

X

 

 

 

 

Participant
Characteristics

 

X

 

Garmin Data

 

X

 

X

X

X

Health Resource Data

 

 

 

X

X

X

Process Outcomes
Data

 

 

 

X

X

X

Referral to Services†

 

 

O

Self-Report Data Collection — Carer
BFI (10 items)

5

 

iVICQ (14 items)
Interview†

10
15

 
 

X
X
 

 
 
 

 

O

O

 

 

 

 

X
X
 

X
X
 

X
X
X

*Data collection will occur as close as practically possible to the timepoint.
†Only completed for participants in the telehealth cancer-related fatigue intervention group.
AAS, The Active Australia Survey; AES-S, self-reported apathy; BFI, Brief Fatigue Inventory; iVICQ, institute for Medical Technology
Assessment Valuation of Informal Care Questionnaire; MSAS, Memorial Symptom Assessment Scale; O, conducted by intervention nurse;
PG-SGA SF, Patient-Generated Subjective Global Assessment Short Form; T, time point; X, conducted by research assistant.

retention and attrition rates, adherence) as well as clinical
and resource-use outcomes (eg, fatigue, physical activity,
hospital resource utilisation). Preliminary effect size estimates for cancer survivor and resource use outcomes will
be calculated following intention-to-treat principles using
linear mixed models to account for repeated measures
and missing data. Effect sizes will be reported as estimates
with a 95% CI, and without p values due to the underpowered nature of the study. Models will include group, time
and their interaction and be adjusted by fatigue severity
and current cancer treatment. Balance of demographic
variables between the usual care and intervention group
will be examined and adjusted for potential confounders.
Assumptions of all models (normality, linearity, homoscedasticity) will be examined using the residuals of the
model and will be described using mean, median, skewness, kurtosis and plots such as histograms and QQ-plots.
If assumptions are violated, models will be either bootstrapped or log transformed, as appropriate. Missing data
8

will be explored using descriptive statistics. Generalised
linear models will be used to provide estimates for categorical outcomes such as adherence, with appropriate link
models used based on the outcome distribution. All statistical analysis will be undertaken by an independent statistician blinded to treatment allocation. Semistructured
interviews will be audio or video recorded and will be
transcribed verbatim for thematic analysis; a method for
systematically identifying, organising and offering insight
into, patterns of meaning (themes) across a dataset.40
DATA MANAGEMENT
Data management and confidentiality
All data will be recorded in electronic case report forms.
Participants will only be identified by a unique participant
study number on the case report forms and other documents. A secure system for online and offline data capture
will be used for direct data entry by both participants
Ladwa R, et al. BMJ Open 2022;12:e059952. doi:10.1136/bmjopen-2021-059952
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Table 3 Study schedule for data collection

Open access

Outcome domain
Process measures
Apathy

Specific measurement

Metric and method of
aggregation

Time-point of interest

Effect of time on mean
change score between
groups

Baseline, 12 weeks, 24 weeks
and 48 weeks

 

12 weeks, 24 weeks and 48
weeks

Adherence and fidelity:
referrals to allied health and
community services

 
Number and type of allied
health and community service
referrals raised and number
actioned and attended as
reported by research assistant,
intervention nurse or cancer
survivor participant and
verified with electronic hospital
medical records

12 weeks, 24 weeks and 48
weeks

Treatment fidelity among
programme administrators:
intervention delivery

Audio and video recording of
telehealth sessions.

 

12 weeks, 24 weeks and 48
weeks

Intervention functionality,
Semistructured interviews
acceptability and satisfaction. with stakeholders (ie, cancer
survivor participants, carer
participants, CCQ nurses,
other healthcare providers)
to discuss acceptability,
and barriers and facilitators
to implementing of T-CRF
intervention.

 

48 weeks

Self-Reported Apathy
Evaluation Scale39

Adherence and fidelity among Completion of items on the
programme administrators:
nurse clinic checklist and
completion of clinic records booster phone checklist.

Recruitment and attrition

Information from research
 
assistant records and hospital
records.

Baseline, 48 weeks.

Fatigue

Brief Fatigue Inventory (BFI)32

Effect of time on mean
change score between
groups

Baseline, 12 weeks, 24 weeks
and 48 weeks

Symptom distress

Memorial Symptom
Assessment Scale44

Effect of time on mean
change score between
groups

Baseline, 12 weeks, 24 weeks
and 48 weeks

Physical activity (subjective)

Active Australia Survey45
International Physical Activity
Questionnaire short-form46
Number of steps per day,
number of stairs climbed
per day, total hours doing
moderate intensity exercise
per day, and total hours slept
per day as measured by
Garmin wrist-worn activity
tracker (VívoSmart 4, Garmin
Australasia Pty Ltd, NSW,
Australia)

Effect of time on mean
change score between
groups
Effect of time on mean
change score between
groups

Baseline, 12 weeks, 24 weeks
and 48 weeks

Clinical outcome measures

Physical activity (objective)

Baseline, 12 weeks, 24 weeks
and 48 weeks

Continued

Ladwa R, et al. BMJ Open 2022;12:e059952. doi:10.1136/bmjopen-2021-059952
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Table 4 Study outcome measures

Open access

Metric and method of
aggregation

Outcome domain

Specific measurement

Time-point of interest

Productivity loss

Incidence and severity
of financial distress and
employment interference as
measured by a 3-item survey
developed by the research
team.47 48

Effect of time on mean
change score between
groups

Baseline, 12 weeks, 24 weeks
and 48 weeks

Hospital resource utilisation

Electronic hospital medical
records

Number of hospital
admissions and emergency
presentations

Baseline, 12 weeks, 24 weeks
and 48 weeks

Carer’s fatigue

BFI32

Effect of time on mean
change score between
groups

Baseline, 12 weeks, 24 weeks
and 48 weeks

Carer’s productivity loss

Modified version of the
Institute for Medical
Technology Assessment
Valuation of Informal Care
Questionnaire.49

Effect of time on mean
change score between
groups

Baseline, 12 weeks, 24 weeks
and 48 weeks

Cancer survivor participant characteristcs
Demographics

Participant interview

Clinical characteristics

Participant interview
Malnutrition Screening Tool50

Collection of age, gender,
Baseline
ethnicity, education, living
arrangements, marital status
and employment
Past and current medical
Baseline
conditions and syndromes,
current medications and
supplements, cancer
diagnosis, previous cancer
treatment, current cancer
treatment and fatigue history
using participant interview,
and nutrition risk

CCQ, Cancer Council Queensland; T-CRF, telehealth cancer-related fatigue.

and research staff. Case report forms will be accessed
by the project manager for data checking. Data queries
will be generated and sent to the relevant research team
member for response before the database is locked and
released for statistical analysis. Other study-related documents (eg, signed informed Participant Information and
Consent Form (PICF)) will be kept in strict confidence by
the Chief Investigator.
Data checking
Data will be directly entered into REDCap by members of
the research team using a tablet or desktop computer. All
research team members will receive training regarding
data collection from the Project Manager. To maximise
data integrity and completeness, the project manager will
undertake routine audits with data validation performed
via REDCap. Any discrepancies and missing data will
be alerted and resolved with the relevant research team
member(s) as soon as practical. All electronic case report
forms will be maintained on the system with details of any
changes logged accordingly.
10

Data protection
Participants will be informed that data will be archived at
PAH and that these data may be viewed by staff including
the project manager and by external auditors on behalf
of PAH and appropriate regulatory authorities including
Metro South Health Human Research Ethics Committee
(MSH HREC) and PAH Research Governance. Participants will be informed that a study report will be
submitted to regulatory authorities and for publication
and conference presentation. However, participants will
be deidentified in such reports with only their study identification number, gender and age used for recording or
linkage purposes.
Data retention
Audio and video recordings of the telehealth intervention will be stored electronically at Queensland University
of Technology in a secure repository and will be securely
destroyed after analysis is conducted. All other source
data, clinical records and laboratory data relating to the
study will be archived at PAH for at least 15 years after
Ladwa R, et al. BMJ Open 2022;12:e059952. doi:10.1136/bmjopen-2021-059952
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Table 4 Continued

Open access

PATIENT AND PUBLIC INVOLVEMENT
To ensure cancer survivor perspectives were represented
and accommodated in the intervention design and implementation, the patient support and advocacy group at
CCQ were invited, have provided input into the study.
Consumers were invited to provide comments and critical
appraisal of the study protocol. They will also assist with
raising the profile of the study through their consumer
and clinical networks. CCQ will also be providing the
intervention cancer nurses who will deliver the T-CRF
clinics.

ETHICS AND DISSEMINATION
Prior to the commencement of the study, written
approval was acquired by MSH HREC (ID: HREC/2020/
QMS/63495), with Research Governance approval
provided by the PAH Research Governance Office. This
study will be conducted in accordance with the principles
of the Declaration of Helsinki,41 Good Clinical Practice
(CPMP/ICH/135/95)42 and the National Health and
Medical Research Council National Statement on Ethical
Conduct in Research Involving Humans.43
Archiving and regulatory inspection
In accordance with the guidance on Good Clinical Practice (GCP), this study may be selected for audit. Inspection of site facilities and review of study-related records
may occur by a representative of the responsible organisation or regulatory authority to evaluate the study conduct
and compliance with the protocol, GCP and applicable
regulatory requirements. All study-related documents and
records will be retained for a minimum of 15 years after
trial completion. Written agreement from the responsible
organisation will precede destruction of the same.
Dissemination
Publication and reporting of results and outcomes of this
trial will be accurate and honest, undertaken with integrity and transparency. Trial results will be disseminated
to all participants with a summary sheet that will outline
the trial findings in lay language. It is intended that the
findings from this trial will be disseminated at academic,
Ladwa R, et al. BMJ Open 2022;12:e059952. doi:10.1136/bmjopen-2021-059952

clinical and professional conferences, and published in
high-quality, international peer-reviewed journals.
Protocol amendments and deviation
Neither the principal investigator nor the PAH will
modify or alter this protocol without the agreement of
the other. All agreed protocol amendments will be clearly
recorded on a protocol amendment form and will be
signed and dated by the original protocol approving
signatories. All protocol amendments will be submitted
to the MSH HREC for approval before implementation.
The only exception will be when the amendment is necessary to eliminate an immediate hazard to the trial participants. In this case, the necessary action will be taken first,
with the relevant protocol amendment following shortly
thereafter. Should any protocol deviation occur, it will be
reported to the study project manager as soon as is practical. The deviation and the reason for its occurrence will
be included in the study report.

TRIAL STATUS
This protocol (V.1.1) was approved and registered on the
Australian New Zealand Clinical Trial Registry (ANZCTR)
on the 10 December 2020 (ID: ACTRN12620001334998).
The study started recruitment on 17 February 2021, and
as of 1 November 2021, 40 cancer survivor participants
and 16 carers have been enrolled. Data collection is anticipated to conclude in January 2023 (48 weeks following
the final participant enrolled). Data analysis and manuscript preparation are anticipated to occur over 6 months,
concluding in July 2023.
Author affiliations
1
Division of Cancer Services, Princess Alexandra Hospital, Brisbane, Queensland,
Australia
2
Centre for Healthcare Transformation, Queensland University of Technology,
Brisbane, Queensland, Australia
3
Physiotherapy Department, Princess Alexandra Hospital, Brisbane, Queensland,
Australia
4
Cancer Council Queensland, Brisbane, Queensland, Australia
5
Occupational Therapy Department, Princess Alexandra Hospital, Brisbane,
Queensland, Australia
6
Caring Futures Institute, Flinders University, Adelaide, South Australia, Australia
7
School of Medicine, The University of Queensland, Brisbane, Queensland, Australia
8
Digital Health and Informatics, Metro South Health Service District, Brisbane,
Queensland, Australia
9
School of Public Health, The University of Queensland, Brisbane, Queensland,
Australia
10
The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
11
Exercise Medicine Research Institute, Edith Cowan University, Perth, Western
Australia, Australia
12
Institute for Health Research, The University of Notre Dame Australia, Perth,
Western Australia, Australia
Twitter Fiona Crawford-Williams @Fiona_CW1, Nicolas H Hart @DrNicolasHart and
Raymond J Chan @rayychan
Acknowledgements The authors wish to acknowledge Cancer Council
Queensland who have provided feedback on the study and contributed their
telehealth facilities and the cancer nurses who will be delivering the intervention.
Contributors RJC and RL conceptualised the study. RJC, RL, PY, SMM, CPE, JFA
MBP, BH, and GL acquired and received the funding. JT, BH, JFA provided input on

11

BMJ Open: first published as 10.1136/bmjopen-2021-059952 on 16 May 2022. Downloaded from http://bmjopen.bmj.com/ on August 4, 2022 at Edith Cowan University. Protected by
copyright.

study completion and remain available for retrospective review or audit. The investigator and study staff will
be responsible for maintaining a comprehensive filing
system of all essential study-related documentation. All
essential documentation will be retained by PAH as per
the requirements of the responsible organisation for the
same period required for medical records retention. No
study document will be destroyed without written agreement between the PAH and the principal investigator. If
the principal investigator wishes to assign the study records
to another party or move them to another location, they
will notify the responsible organisation in writing of the
new responsible person or the new location.

Open access

Funding This work is financially supported by the Princess Alexandra Research
Foundation (Award Number: RSS_2020_095). RJC (#1194051), PY (#2009529),
and SMM (#1161138) receive salary support from National Health and Medical
Research Council administered fellowships. The funding bodies have no role in
the design of this study and will not have any role during its execution, analyses,
interpretation of the data, or decision to submit results.
Competing interests None declared.
Patient and public involvement Patients and/or the public were involved in the
design, or conduct, or reporting, or dissemination plans of this research. Refer to
the Methods section for further details.
Patient consent for publication Not applicable.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been
peer-reviewed. Any opinions or recommendations discussed are solely those
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and
responsibility arising from any reliance placed on the content. Where the content
includes any translated material, BMJ does not warrant the accuracy and reliability
of the translations (including but not limited to local regulations, clinical guidelines,
terminology, drug names and drug dosages), and is not responsible for any error
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited, appropriate credit is given, any changes made indicated, and the use
is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
ORCID iDs
Oluwaseyifunmi Andi Agbejule http://orcid.org/0000-0003-2925-3362
Fiona Crawford-Williams http://orcid.org/0000-0002-3897-333X
Patsy Yates http://orcid.org/0000-0001-8946-8504
Nicolas H Hart http://orcid.org/0000-0003-2794-0193
Raymond J Chan http://orcid.org/0000-0003-0248-7046

REFERENCES

1 Berger AM, Mooney K, Alvarez-Perez A, et al. Cancer-Related
fatigue, version 2.2015. J Natl Compr Canc Netw 2015;13:1012–39.
2 Molassiotis A, Yates P, Li Q, et al. Mapping unmet supportive care
needs, quality-of-life perceptions and current symptoms in cancer
survivors across the Asia-Pacific region: results from the International
step study. Ann Oncol 2017;28:2552–8.
3 Bower JE, Ganz PA, Desmond KA, et al. Fatigue in breast cancer
survivors: occurrence, correlates, and impact on quality of life. J Clin
Oncol 2000;18:743–53.
4 Rodríguez Antolín A, Martínez-Piñeiro L, Jiménez Romero ME, et al.
Prevalence of fatigue and impact on quality of life in castration-
resistant prostate cancer patients: the vital study. BMC Urol
2019;19:92.
5 Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue
on the lives of patients: new findings from the fatigue coalition.
Oncologist 2000;5:353–60.
6 Lis CG, Rodeghier M, Grutsch JF, et al. Distribution and determinants
of patient satisfaction in oncology with a focus on health related
quality of life. BMC Health Serv Res 2009;9:190.
7 Luthy C, Cedraschi C, Pugliesi A, et al. Patients' views about causes
and preferences for the management of cancer-related fatigue-a
case for non-congruence with the physicians? Support Care Cancer
2011;19:363–70.
8 Banipal RPS, Singh H, Singh B. Assessment of cancer-related
fatigue among cancer patients receiving various therapies: a cross-
sectional observational study. Indian J Palliat Care 2017;23:207–11.
9 Charalambous A, Kouta C. Cancer related fatigue and quality of life
in patients with advanced prostate cancer undergoing chemotherapy.
Biomed Res Int 2016;2016:3989286

12

10 Bower JE. Cancer-related fatigue--mechanisms, risk factors, and
treatments. Nat Rev Clin Oncol 2014;11:597–609.
11 Hofman M, Ryan JL, Figueroa-Moseley CD, et al. Cancer-related
fatigue: the scale of the problem. Oncologist 2007;12 Suppl 1:4–10.
12 Wolvers MDJ, Leensen MCJ, Groeneveld IF, et al. Predictors
for earlier return to work of cancer patients. J Cancer Surviv
2018;12:169–77.
13 Thong MSY, van Noorden CJF, Steindorf K, et al. Cancer-Related
fatigue: causes and current treatment options. Curr Treat Options
Oncol 2020;21:17.
14 Clark MM, Atherton PJ, Lapid MI, et al. Caregivers of patients with
cancer fatigue: a high level of symptom burden. Am J Hosp Palliat
Care 2014;31:121–5.
15 Fletcher BS, Paul SM, Dodd MJ, et al. Prevalence, severity, and
impact of symptoms on female family caregivers of patients at
the initiation of radiation therapy for prostate cancer. J Clin Oncol
2008;26:599–605.
16 Jean-Pierre P, Figueroa-Moseley CD, Kohli S, et al. Assessment
of cancer-related fatigue: implications for clinical diagnosis and
treatment. Oncologist 2007;12 Suppl 1:11–21.
17 Jensen S, Given B. Fatigue affecting family caregivers of cancer
patients. Support Care Cancer 1993;1:321–5.
18 Finnegan-John J, Molassiotis A, Richardson A, et al. A systematic
review of complementary and alternative medicine interventions
for the management of cancer-related fatigue. Integr Cancer Ther
2013;12:276–90.
19 Bohlius J, Tonia T, Nüesch E, et al. Effects of erythropoiesis-
stimulating agents on fatigue- and anaemia-related symptoms in
cancer patients: systematic review and meta-analyses of published
and unpublished data. Br J Cancer 2014;111:33–45.
20 Tomlinson D, Robinson PD, Oberoi S, et al. Pharmacologic
interventions for fatigue in cancer and transplantation: a meta-
analysis. Curr Oncol 2018;25:152–67.
21 Mustian KM, Alfano CM, Heckler C, et al. Comparison of
pharmaceutical, psychological, and exercise treatments for cancer-
related fatigue: a meta-analysis. JAMA Oncol 2017;3:961–8.
22 de Raaf PJ, de Klerk C, Timman R, et al. Systematic monitoring
and treatment of physical symptoms to alleviate fatigue in patients
with advanced cancer: a randomized controlled trial. J Clin Oncol
2013;31:716–23.
23 Agbejule OA, Hart NH, Ekberg S, et al. Bridging the research to
practice gap: a systematic scoping review of implementation of
interventions for cancer-related fatigue management. BMC Cancer
2021;21:809.
24 Escalante CP, Kallen MA, Valdres RU, et al. Outcomes of a cancer-
related fatigue clinic in a comprehensive cancer center. J Pain
Symptom Manage 2010;39:691–701.
25 Escalante CP, Manzullo E, Valdres R. A cancer-related fatigue
clinic: opportunities and challenges. J Natl Compr Canc Netw
2003;1:333–43.
26 Chan RJ, Crichton M, Crawford-Williams F, et al. The efficacy,
challenges, and facilitators of telemedicine in post-treatment cancer
survivorship care: an overview of systematic reviews. Ann Oncol
2021;32:1552–70.
27 Chan A, Ashbury F, Fitch MI, et al. Cancer survivorship care during
COVID-19-perspectives and recommendations from the MASCC
survivorship Study Group. Support Care Cancer 2020;28:3485–8.
28 Monterosso L, Platt V, Bulsara M, et al. Systematic review and
meta-analysis of patient reported outcomes for nurse-led models
of survivorship care for adult cancer patients. Cancer Treat Rev
2019;73:62–72.
29 Tuominen L, Stolt M, Meretoja R, et al. Effectiveness of nursing
interventions among patients with cancer: an overview of systematic
reviews. J Clin Nurs 2019;28:2401–19.
30 Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating
complex interventions: the new medical Research Council guidance.
BMJ 2008;337:a1655.
31 Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. Spirit 2013 explanation
and elaboration: guidance for protocols of clinical trials. BMJ
2013;346:e7586.
32 Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of
fatigue severity in cancer patients: use of the brief fatigue inventory.
Cancer 1999;85:1186–96.
33 Hertzog MA. Considerations in determining sample size for pilot
studies. Res Nurs Health 2008;31:180–91.
34 Julious SA. Sample size of 12 per group rule of thumb for a pilot
study. Pharm Stat 2005;4:287–91.
35 Cancer Council Australia. Fatigue and cancer, 2019.
36 Stout NL, Brown JC, Schwartz AL, et al. An exercise oncology
clinical pathway: screening and referral for personalized
interventions. Cancer 2020;126:2750–8.

Ladwa R, et al. BMJ Open 2022;12:e059952. doi:10.1136/bmjopen-2021-059952

BMJ Open: first published as 10.1136/bmjopen-2021-059952 on 16 May 2022. Downloaded from http://bmjopen.bmj.com/ on August 4, 2022 at Edith Cowan University. Protected by
copyright.

motivational interviewing, counselling techniques, and resources for the nurse-led
intervention. OAA, EPP, JN, LT, FCW and NHH led the design, development, and
writing of the pilot RCT protocol. LJ provided data and statistical analysis methods.
All authors contributed important intellectual content to the trial design and written
protocol and reviewed and approved the final version for publication.

Open access

Ladwa R, et al. BMJ Open 2022;12:e059952. doi:10.1136/bmjopen-2021-059952

44 Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial
symptom assessment scale: an instrument for the evaluation of
symptom prevalence, characteristics and distress. Eur J Cancer
1994;30A:1326–36.
45 Australian Institute of Health and Welfare. The active Australia survey:
a guide and manual for implementation, analysis and reporting.
Canberra: AIHW, 2003.
46 Craig CL, Marshall AL, Sjöström M, et al. International physical
activity questionnaire: 12-country reliability and validity. Med Sci
Sports Exerc 2003;35:1381–95.
47 Chan R, Cooper B, Paul S, et al. Distinct financial distress profiles
in patients with breast cancer prior to and for 12 months following
surgery. BMJ Support Palliat Care 2020:bmjspcare-2020-002461.
48 Chan RJ, Cooper B, Koczwara B, et al. A longitudinal analysis of
phenotypic and symptom characteristics associated with inter-
individual variability in employment interference in patients with
breast cancer. Support Care Cancer 2020;28:4677–86.
49 Hoefman R, Van-Excel NJA, Brouwer WBF. iMTA valuation of informal
care questionnaire, 2013.
50 Ferguson M, Capra S, Bauer J, et al. Development of a valid and
reliable malnutrition screening tool for adult acute hospital patients.
Nutrition 1999;15:458–64.

13

BMJ Open: first published as 10.1136/bmjopen-2021-059952 on 16 May 2022. Downloaded from http://bmjopen.bmj.com/ on August 4, 2022 at Edith Cowan University. Protected by
copyright.

37 Bellg AJ, Borrelli B, Resnick B, et al. Enhancing treatment
fidelity in health behavior change studies: best practices and
recommendations from the NIH behavior change Consortium. Health
Psychol 2004;23:443–51.
38 Robb SL, Burns DS, Docherty SL, et al. Ensuring treatment fidelity
in a multi-site behavioral intervention study: implementing NIH
behavior change Consortium recommendations in the smart trial.
Psychooncology 2011;20:1193–201.
39 Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of
the apathy evaluation scale. Psychiatry Res 1991;38:143–62.
40 Braun V, Clarke V. Thematic analysis. In: Cooper H, Camic PM,
Long DL, et al, eds. APA Handbook of research methods in
psychology, vol. 2: research methods: quantitative, qualitative,
neuropsychological, and biological. Washington, DC: American
Psychological Association, 2012: 57–71.
41 World Medical Association declaration of Helsinki. Recommendations
guiding physicians in biomedical research involving human subjects.
JAMA 1997;277:925–6.
42 Therapeutic Goods Administration. Note for guidance on good
clinical practice (CPMP/ICH/135/95), 2000.
43 National H, Medical Research C, Australian Research C, Australian
Vice-Chancellors C. National statement on ethical conduct in human
research 2007 (updated 2018). Canberra: National Health and
Medical Research Council (NHMRC), 2007.

